TABLE 2.

The effects of pre-treatment with dibenzazepine on the oxidative stress markers in the cisplatin-injected rats.

Treated groups	GSH (mg/mg protein)	MDA (nmol/mg protein)	CAT (mg/mg protein)
Control	98.31 ± 4.68 a	39.89 ± 1.35 a	2.10 ± 0.23 a
Cisplatin	48.90 ± 5.03 b	69.50 ± 4.06 b	0.88 ± 0.07 b
Cisplatin/Dibenzazepine	83.35 ± 1.09 a,b	48.25 ± 1.66 a,b	1.72 ± 0.06 a,b
Dibenzazepine	94.44 ± 3.23 a	42.32 ± 2.48 a	1.93 ± 0.04 a

Each value indicates the mean ± SD of six observations.

^aSignificantly different from the control or cisplatin group, respectively at p < 0.05 using ANOVA followed by Tukey–Kramer, as a post-hoc test.

^bSignificantly different from the control or cisplatin group, respectively at p < 0.05 using ANOVA followed by Tukey–Kramer, as a post-hoc test.

GSH, glutathione; MDA, malondialdehyde; CAT, catalase.